www.alopeciaworld.com
I have received a lot of interest from others on here in my involvement with the Xeljanz trials at Yale.
I thought it would be nice for everyone if I documented my progress on here.
Xeljanz is a Jak3 inhibitor and is believed to work with alopecia by turning off the distress signal relayed by the hair follicle to the attacking immune system which is the cause of the hairs falling out. Xeljanz comes in a strength of 5mg per pill and a full box contains 60 tablets. The recommended dosage for arthritis is 1 tablet in the morning and another in the evening each day.
The trial is set in a series of stages and there are requirements before participating. These include monthly visits and blood tests every 2 weeks. Dr Brett King is absolutely fantastic and is an inspiration to me. His positivity and enthusiasm gives me the much needed hope I have craved for over a decade. I have been put on a low dose to start with which is 1 tablet every other day. My dosage has now been increased to 1 tablet every day and next month it could be increased to 2 tablets per day depending on the results.
I have completed my first month and have already noticed my alopecia has stabilised . I have not lost any existing hairs. In addition to this I have seen little hairs growing in my chest area as well as eyebrows. Fingers crossed! To date, I have experienced no side effects.
-----------------------------
AW: Other discussions on Xeljanz / Tofacitinib
https://alopeciaworld.com/main/search/search?q=Tofacitinib
Tags:
Hello Toks,
We haven't heard from you in a long time and wonder how you are doing on Xeljanz. Are you still buying it in Turkey?
http://www.sciencedirect.com/science/article/pii/S2352396415000638
For those living in a country where Xeljanz is not approved the upcoming Jak1/2 inhibitor Baricitinib might be a solution in about 1 to 1,5 years time I reckon.
Xeljanz is mainly inhibiting Jak1/3 (also jak2 a little bit). This results in blocking il-15 (which signals through jak1/3) which is linked to Alopecia.
Baricitinib is only inhibiting Jak1/2. This results in blocking IFN-y (which signals through jak1/2) which looks to be highly elevated in alopecia patients.
The only problem with inhibiting jak2 is the chance of getting anemia. As EPO production is signaled through jak2.
The advantage of baricitinib over Xeljanz however would be the safety profile. This will be much better as it's sparing Jak3 so you are disfiguring the immune system less.
Anyway exiting times ahead..
Any mention of products and services on Alopecia World is for informational purposes only; it does not imply a recommendation or endorsement by Alopecia World. Nor should any statement or representation on this site be construed as professional, medical or expert advice, or as pre-screened or endorsed by Alopecia World. Alopecia World is not responsible or liable for any of the views, opinions or conduct, online or offline, of any user or member of Alopecia World.
© 2024 Created by Alopecia World. Powered by